GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » Net Issuance of Preferred Stock

Anteris Technologies Global (ASX:AVR) Net Issuance of Preferred Stock : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies Global Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Anteris Technologies Global's net issuance of preferred for the six months ended in Dec. 2024 was A$0.00 Mil. The number is 0, which means that Anteris Technologies Global has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Anteris Technologies Global's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.


Anteris Technologies Global Net Issuance of Preferred Stock Historical Data

The historical data trend for Anteris Technologies Global's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Global Net Issuance of Preferred Stock Chart

Anteris Technologies Global Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anteris Technologies Global Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Anteris Technologies Global Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies Global Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Anteris Technologies Global's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies Global Business Description

Traded in Other Exchanges
N/A
Address
9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.